Back to Search Start Over

Life expectancy of young adults with follicular lymphoma.

Authors :
Conconi A
Lobetti-Bodoni C
Montoto S
Lopez-Guillermo A
Coutinho R
Matthews J
Franceschetti S
Bertoni F
Moccia A
Rancoita PM
Gribben J
Cavalli F
Gaidano G
Lister TA
Montserrat E
Ghielmini M
Zucca E
Source :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2015 Nov; Vol. 26 (11), pp. 2317-22. Date of Electronic Publication: 2015 Sep 11.
Publication Year :
2015

Abstract

Background: This study was aimed at investigating the clinical features and outcomes of follicular lymphoma (FL) patients younger than 40 years, which have not been extensively investigated yet.<br />Patients and Methods: One hundred and fifty-five patients younger than 40 years were retrospectively studied from a series of 1002 FL patients diagnosed in four different European Oncology Centres (Barcelona, Spain; Bellinzona, Switzerland; London, UK; Novara, Italy) from 1985 to 2010.<br />Results: Patients younger than 40 had a lower incidence of elevated LDH, high beta2-microglobulin, and a high-risk Follicular Lymphoma International Prognostic Index (FLIPI) score, whereas bone marrow involvement and bulky and disseminated lymphadenopathy were more frequent. At a median follow-up of 10 years, younger patients, in comparison with those older than 40, had significantly better overall (OS), cause-specific survival (CSS), and progression-free survival (PFS), with 10-year OS rate of 81% versus 51% (P < 0.0001), 10-year CSS rate of 82% versus 60% (P < 0.0001), and 10-year PFS of 39% versus 24% (P = 0.0098). However, there were no significant CSS and PFS differences in comparison with the patients aged 40-60. In multivariate analysis, having the lymphoma diagnosed in the last two decades and a favourable FLIPI score were associated with a significantly longer PFS and CSS in younger patients, whereas only FLIPI retained statistical significance for OS.<br />Conclusions: In our series, FL patients younger than 40 have a median OS of 24 years and their outcome seems to be improving over time. However, they still have a significantly shorter life expectancy than that of an age-matched general healthy population.<br /> (© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Details

Language :
English
ISSN :
1569-8041
Volume :
26
Issue :
11
Database :
MEDLINE
Journal :
Annals of oncology : official journal of the European Society for Medical Oncology
Publication Type :
Academic Journal
Accession number :
26362567
Full Text :
https://doi.org/10.1093/annonc/mdv376